Ahmad et al 1 have recently reported their results in four cases of VAD-refractory multiple-myeloma (MM) salvaged with thalidomide (Thal)+VAD followed by peripheral blood stem cell transplantation (PBSCT).
All patients underwent stem cell mobilization with cyclophosphamide (CTX) and GM-CSF. Melphalan was given as conditioning, and all patients engrafted within 12-16 days after PBSCT. Two patients continue to take Thal after a median follow-up of 153 days with no signs of disease progression. They suggest that Thal and other related immunomodulatory drugs may prove useful for initial MM therapy in combination with standard chemotherapy followed by PBSCT. These conclusions must be interpreted with caution. Firstly, when Thal is continued during stem cell mobilization some decrease in circulating peripheral stem cells has been reported. Munshi et al 2 have recently reported that when the first 3 days of apheresis were considered the median CD 34+ yield was 5.2 with Thal and 15 without Thal (P ¼ 0.01).
In our experience, 10 MM patients were randomized upfront to receive additional Thal at 400 mg daily; after stem cell mobilization with CTX plus G-CSF, the median CD34 yield ( Â 10 6 kg) was 3.7 (range 1-12) with Thal and 7.8 (range 2.6-18.7) without Thal (P ¼ 0.01). The process of stem cell mobilization involves modulation of adhesive interactions between bone marrow stroma and hematopoietic stem cells, Thal seems to modulate these adhesion molecules (integrins, selectins and immunoglobulinlike) with a reduction of circulating CD 34+ after mobilization. 3, 4 Also, transplants should therefore not be attempted with minimally adequate numbers of stem cells reinfused since Thal could also hamper the adhesive process mediated by L-selectin. 5 Secondly, Thal given in combination with multiagent chemotherapy and dexamethasone is associated with a significantly increased risk of deep vein thrombosis(DVT) that has important clinical implications. 6 Thal is the most active single agent discovered in the last three decades. 
